Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bea 2180
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
BEA 2180 (also referred to as BEA 2180 BR) is an investigational anticholinergic agent developed for the treatment of chronic obstructive pulmonary disease (COPD). It acts as a bronchodilator and has been evaluated in clinical trials for its efficacy and safety in improving lung function, reducing symptoms and exacerbations, and enhancing health status in patients with COPD. In comparative studies, BEA 2180 demonstrated noninferiority to tiotropium regarding improvements in forced expiratory volume (FEV1) and symptom scores. The drug was generally well tolerated across studied doses[1][4]. Pharmacokinetic studies have also been conducted to assess its metabolism and tolerability in healthy volunteers[2]. Boehringer Ingelheim is the developer and manufacturer. The mechanism of action is antagonism of the muscarinic acetylcholine receptor.
- Other names
- bea 2180 alcohol-d3bea2180 alcohol-d3bea-2180 alcohol-d3
02
Targets
mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on bea 2180.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bea 2180.